Abbott Agrees to $670M Settlement Covering 2,000 NEC Claims on Preterm Infant Formula (NYSE: ABT)

Abbott Laboratories (NYSE: ABT) has reached a $670 million agreement with three law firms to resolve the Gill lawsuit and approximately 2,000 related necrotizing enterocolitis (NEC) claims tied to its specialty formulas for preterm infants. The settlement bypasses the appeals process, drawing a line under one of the most protracted legal battles facing the company. Shares gained 2.19% on Friday, August 21, 2026, while the S&P 500 rose 0.41%.

Settlement Terms

• $670 million total settlement amount agreed with three law firms representing claimants in the Gill case and related proceedings.
• Covers approximately 2,000 individuals whose claims involve Abbott's specialty formulas designed for preterm infants.
• Abbott elected to bypass the appeals process, indicating a preference for a definitive resolution rather than continued litigation risk.
• The agreement was reached with three unnamed law firms, according to Benzinga reporting dated August 20-21, 2026.

Why It Matters

NEC litigation has been a significant legal overhang for Abbott, with thousands of plaintiffs alleging that the company's preterm infant formulas contributed to necrotizing enterocolitis, a serious gastrointestinal condition affecting premature newborns. By settling without pursuing further appeals, Abbott removes the uncertainty of additional adverse verdicts or expanded liability that could have accompanied a prolonged appellate process.

The $670 million figure represents a defined cash outflow against a litigation pool that had the potential to grow. Abbott's decision to consolidate resolution across roughly 2,000 claims in a single structured settlement limits the compounding costs of managing each case individually through the courts.

Wall Street View

Analyst sentiment on Abbott remains broadly constructive. As of August 1, 2026, the consensus stood at 11 Strong Buy and 13 Buy recommendations, with 9 Hold ratings and no Sell or Strong Sell calls. The settlement removes a meaningful legal uncertainty that had been factored into analyst risk assessments, though the $670 million outflow will weigh on near-term cash metrics.

Investor Takeaway

For investors, the settlement trades a defined $670 million cash cost for the elimination of open-ended litigation exposure across approximately 2,000 NEC claims, a resolution that may prove less costly than a protracted appeals process with unpredictable outcomes. The more consequential question going forward is whether the three-firm agreement closes the door on NEC liability entirely, or whether additional claimants outside this settlement remain in the pipeline. That distinction will determine whether Friday's relief in the share price reflects a full clearing event or only partial resolution of Abbott's legal risk profile.